Colorectal cancer (CRC) is known as the third leading cause of cancer mortality worldwide, propagating by the acquisition of several genetic alternations influencing the expression and function of target genes. Adenomatous Polyposis Coli and *TP53* are the most commonly mutated genes in familial/inherited and sporadic CRC \[[@B1]\]. CRC metastasis is a common phenomenon and the major lethal cause of CRC cases, as approximately 50% of CRC patients die within 5 years due to extensive metastatic stage \[[@B2]\]. So far, however, there has been little information about the molecular mechanisms underlying the ability of CRC cells to become invasive. Numerous studies have proved that the transition of CRC cells from early stages to late stages (metastasis) is associated with a significant change in the cellular gene expression profile \[[@B3]\]. These genetic alterations have led to the emergence of the novel strategies for personalized medicine programs \[[@B4]\]. As a result, Zhao *et al*. found an apparent difference between protein expression profile of nonmetastatic and metastatic CRC cell lines. They concluded that overexpression of *HSP27* might play a key role in the acquisition of invasion and migratory properties by CRC cells \[[@B5]\]. Furthermore, Tan *et al*. introduced *STMN1* gene as a crucial player in CRC cell migration and prognostic marker through a comparative proteome analysis of primary CRC cell lines HCT-116 and its metastatic derivative E1 \[[@B6]\]. Most recently, we have identified HOXB family as the most significant functional modules in metastatic CRC samples using a network biology approach. Consequently, we proposed a rationally designed anti-*HOXB7* peptide for preventing CRC metastasis \[[@B7]\]. Despite, these valuable studies, the benign-to-malignant transition of CRC is a complicated multistep process and needs to be further elucidated in greater details.

Nowadays, computational systems biology has become a focus of many researchers to decipher complex biological systems through integrating the experimental and computational approaches \[[@B8]\]. Among the currently available methods, reconstruction of protein--protein interaction (PPI) networks are widely used for identification of key genes and functional modules involved in the cancer initiation and progression \[[@B9],[@B10]\]. There are several network-based methodologies for modeling of biological systems that result in an identification of novel biomarkers in the human cancers and complex diseases \[[@B11]\]. To the best of our knowledge, no attempt has yet been made to monitor the dynamic changes of regulatory networks from normal to distant metastasis of the patients with CRC. Accordingly, no effective biomarkers have been introduced for detecting the early events of CRC metastasis. Hence, we assessed the gene expression changes of normal versus stage I (N-S~I~), stage I versus stage II (S~I~-S~II~), stage II versus stage III (S~II~-S~III~) and stage III versus stage IV (S~III~-S~IV~) of CRC cells to propose a biological model for CRC initiation, progression and invasion to other tissues. Additionally, the overlapping mechanisms between four studied CRC stages were elaborated in more details The observations uncovered that several common genes and subnetworks seem to be associated with CRC initiation and metastasis. These findings would help to gain insights into the major contributors involved in the regulation of CRC initiation, progression and invasion. Our study also provides novel potential biomarkers which can be considered to be therapeutic candidates for designing novel drugs with anti-CRC activity.

Materials & methods {#S0001}
===================

Microarray gene expression data {#S0002}
-------------------------------

A gene expression dataset (Gene Expression Omnibus \[GEO\] accession number: GSE21510) consisting of total 148 microarray samples were chosen from (GEO; [www.ncbi.nlm.nih.gov/geo/](http://www.ncbi.nlm.nih.gov/geo/)). The samples had been accumulated from LCM and homogenized tissues of patients with colorectal cancer. Subsequently, the samples separately normalized using robust multiarray average method under R 2.6.2 statistical software with affy package from BioConductor. There was only one sample for stage 0, therefore, we excluded this stage from the study. Differentially expressed genes (DEGs) were determined by using the GEO2R tool \[[@B12]\]. Fold change \> 1 or \< −1 and p-value \< 0.05 are the thresholds used in DEGs determination.

PPI networks {#S0003}
------------

A comprehensive PPI was constructed for each stage using BisoGenet plugin of Cytoscape \[[@B13]\]. This plugin is a multitier application that builds the PPI based on the biomolecular relationships data curated from several PPI databases, including Database of Interacting Proteins, Biological General Repository for Interaction Datasets, Human Protein Reference Database, Biomolecular Interaction Network Database, Molecular INTeraction database (MINT) and IntAct \[[@B14]\]. In parallel, an intensive literature search was conducted to retrieve new PPIs from the data of most recent studies. The PPI networks were visualized and analyzed by Cytoscape and FunRich packages \[[@B20]\].

Identification of hub genes {#S0004}
---------------------------

Topological properties of the PPI networks were interpreted to detect the paramount functional hub genes. We used Network Analyzer, a network analysis plug-in of Cytoscape, to calculate the different topological parameters of resulted PPI networks. To this end, nine measures including Number of Undirected Edges, Degree, Betweenness Centrality, Clustering Coefficient, Closeness Centrality, Eccentricity, Neighborhood Connectivity, Topological Coefficient and Average Shortest Path Length were calculated for each PPI network.

Gene ontology (GO) & signaling pathway enrichment {#S0005}
-------------------------------------------------

Gene ontology (GO) studies were carried out utilizing Biological Networks Gene Ontology tool, a flexible and extendable Cytoscape\'s plugin \[[@B21]\]. This plugin finds GO terms over-represented in the given biological networks. Enrichr server was used as an alternative tool for validating the results of Biological Networks Gene Ontology tool \[[@B22]\]. A p-value less than 0.05 was chosen as the cut-off criterion for statistically over-represented GO terms. A signaling pathway enrichment was performed using SPEED web tool to identify the paramount signaling pathways underlying CRC initiation and invasion \[[@B23]\]. This server is a signaling pathway annotation tool that performs pathway enrichments based on the data obtained from previous pathway perturbation experiments.In parallel, the signaling pathways corresponding to the DEGs were also checked with the Kyoto Encyclopedia of Genes and Genomes \[[@B24]\]. This database consists of throughput information about genomic, cellular pathways and chemical compounds.

Construction of DEG-GO network for S~IV~ of CRC {#S0006}
-----------------------------------------------

After determining DEGs of stage IV gene expression profile compared with the normal samples, a DEG-GO network was constructed to distinguish the major regulators of significantly over-represented GO terms. First, the up-regulated DEGs were separated and their biological roles were determined using DAVID server to understand the activated molecular mechanisms and signaling pathways in metastatic CRC cells compared with their adjacent normal tissue. The GO terms with p-value \< 0.05 containing at least ten genes were considered to be significantly over-represented categories. Finally, a DEG-GO network was constructed and topological analysis of the network was performed using out-degree (the number of outgoing edges) and in-degree (the number of incoming edges) measures.

Identification of common regulatory networks between CRC stages {#S0007}
---------------------------------------------------------------

Stages 1--4 of CRC may share several common genes or modules and identification of these similarities can be helpful in CRC therapy programs. To this end, all DEGs obtained from the comparison of four stages with their adjacent normal tissues (with fold change \>1 and \<−1 and p-value \< 0.05) were clustered using Venny 2.1 web tool \[[@B25]\]. The main subnetwork for both common up and down-regulated DEGs were separately extracted and interpreted. In parallel, GO analysis of common DEGs was conducted to understand the regulatory functions of these genes.

Cell culture, RNA extraction & real-time PCR {#S0008}
--------------------------------------------

In order to validate the *in silico* findings, the expression level *ATXN1* and *CDK1*, identified as hub genes in S~IV~ of CRC, was quantified in human metastatic colon carcinoma cell line (SW620 cells) compared with NCM460, a normal human colon mucosal epithelial cell line. Briefly, SW620 and NCM460 cell lines were seeded in Dulbecco\'s modified Eagle\'s medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. Total RNA was extracted from SW620 and NCM460 cell lines (15--30 mg) using the miRNeasy Kit according to the manufacturer\'s instructions (Qiagen, USA). Subsequently, cDNA synthesis was performed utilizing a commercial cDNA synthesis kit (2-step RT-PCR kit, Vivantis, USA). The standard SYBR green-based quantitative real-time PCR (qRT--PCR) analyses were carried out in Real-time PCR Detection System ABI 7300 (Applied Biosystems, USA). Primer sequences of *ATXN1*, *CDK1* and *GAPDH*, as internal control, are as follows: *ATXN1*-F (5′ CCCACCTTTCCCCTGCTGCG-3′), *ATXN1*-R (5′-GGTTCCTCCCCCGGGTCTCC-3′), *CDK1*-F (5′-GGAAACCAGGAAGCCTAGCA-3′), *CDK1*-R (5′-TGATTCAGTGCCATTTTGCC-3′), *GAPDH*-F (5′-TCCACCACCCTGTTGCTGTAG-3′) and *GAPDH*-R (5′-GGTTCCTCCCCCGGGTCTCC-3′). PCR cycling conditions were conducted in a total volume of 20 μl and containing 10 pmol of each primer and 2 μl of diluted cDNA template (800 ng cDNA). The thermal cycler conditions were composed of an initial step at 95°C for 5 min followed by 45 cycles of 95°C for 15 s, 60°C for 1 min and 72°C for 30 s and a step of 82°C for 5 s. To generate standard curves, the tenfold serial dilutions covering a range of the eluted cDNA was considered as a template in SYBR green qRT-PCR.

Statistical analysis {#S0009}
--------------------

Statistical analysis of *in vitro* experiment was done using GraphPad Prism version 4 (GraphPad Software, CA, USA). P-values were calculated by two-sided Student\'s *t*-test and the values below 0.05 were considered to be significant.

Results {#S0010}
=======

PPI networks properties {#S0011}
-----------------------

A PPI network was constructed for each CRC stage based on the experimentally validated PPI interactions. The PPI networks included 214 nodes and 169 edges (for PPI network of S~I~), 179 nodes and 219 edges (for PPI network of S~II~), 196 nodes and 152 edges (for PPI network of S~III~), and 203 nodes and 146 edges (for PPI network of S~IV~). A decreasing tendency of the distribution of node degree implicated a biological scale-free pattern of four constructed PPI networks (data not shown). The main subnetworks were extracted from each PPI network which is illustrated in [Supplementary Figure 1](http://www.future-science.com/doi/suppl/10.4155/fsoa-04-278-s1.docx). *CDK1*, *UBC*, *ESR1* and *ATXN1* genes had the highest degree of connectivity in the main subnetworks of S~I~, S~II~, S~III~ and S~IV~, respectively.

Hub genes of each PPI network {#S0012}
-----------------------------

Topological analysis of the PPI networks revealed several hub genes as major regulators of CRC initiation, progression and invasion. The results of all topological measures had a relatively high overlap. Interestingly, many of cell cycle-related genes were identified as hub genes in their corresponding PPI networks. The top ten hub genes derived from interpretation of each PPI network are listed in [Table 1](#T1){ref-type="table"}.

###### **Top 10 hub genes identified from analysis of each protein--protein interaction network.**

  **NumUndE**                      **D**      **BetCen**   **CluCoe**   **CloCen**   **E**      **NeiCon**   **TopCoe**   **Avg.ShoPat**
  -------------------------------- ---------- ------------ ------------ ------------ ---------- ------------ ------------ ----------------
  **Hub genes of S~I~ of CRC**                                                                                            
                                                                                                                          
  CDK1                             CDK1       PALB2        CKS2         NUP37        PPAT       FBXO5        NUP37        CBX3
                                                                                                                          
  NPM1                             NPM1       CDK1         NIFK         NUP160       PAICS      TOP2A        NUP160       EXOSC3
                                                                                                                          
  CCNB1                            CCNB1      CSE1L        SKP2         NUP107       DIMT1      PTTG1        NUP107       EEF1E1
                                                                                                                          
  SNRPD2                           SNRPD2     GNL3         CENPE        PALB2        POLR1B     KIF20B       SKP2         HELLS
                                                                                                                          
  BUB1                             BUB1       BCCIP        NUP37        CD44         RPP40      CEP55        SPC25        HSPE1
                                                                                                                          
  CKS1B                            CKS1B      NOP58        NUP160       MAD2L1       HELLS      DDX21        CENPE        RPP40
                                                                                                                          
  DKC1                             DKC1       NPM1         DTL          PPARD        EEF1E1     CPSF3        DTL          POLR1B
                                                                                                                          
  RFC4                             GART       DKC1         NUP107       NCAPG2       EXOSC3     NUDCD1       NIFK         DIMT1
                                                                                                                          
  RFC5                             KIF11      KPNA2        SPC25        SMC2         CBX3       CDC25C       NUF2         EXOSC8
                                                                                                                          
  DTL                              EXOSC3     CCNB1        PPP40        NUF2         KIF20B     NUP107       CDK1         NPM1
                                                                                                                          
  **Hub genes of S~II~ of CRC**                                                                                           
                                                                                                                          
  UBC                              UBC        UBC          CEBPG        UBC          SORBS1     DNAJC5       SORBS1       SLC35D1
                                                                                                                          
  YWHAB                            YWHAB      AURKA        ATXN3        YWHAB        WIF1       JAG1         ZFP36L2      ZNF713
                                                                                                                          
  AURKA                            AURKA      DNAJB12      NCOA6        AURKA        KLHL29     SLC25A23     PARD6B       MBTPS2
                                                                                                                          
  SNRNP200                         SNRNP200   YWHAB        CASK         SNRNP200     YWHAB      PROCR        AAR2         SYK
                                                                                                                          
  CEBPB                            CEBPB      EIF6         TPX2         EIF4E2       AURKA      G2E3         TPX2         PXMP4
                                                                                                                          
  AMOTL2                           AMOTL2     SNRNP200     TLK2         ARAF         SNRNP200   TRERF1       NUF2         DYNLRB1
                                                                                                                          
  TOP1                             COPS6      EIF4E2       PDHA1        CDC25C       EIF4E2     PIGU         TLK2         TMEM189
                                                                                                                          
  ARAF                             ARAF       CEBPB        CTNNBL1      TNFAIP3      ARAF       ZNF687       MAPRE1       RALGAPB
                                                                                                                          
  COPS6                            TOP1       AMOTL2       HERC5        CEBPB        CDC25C     DUSP1        CEBPG        ARFGAP1
                                                                                                                          
  EIF4EB                           CDC25C     TPX2         CEBPB        CASK         TOP1       AURKA        PDHA1        ZNF687
                                                                                                                          
  **Hub genes of S~III~ of CRC**                                                                                          
                                                                                                                          
  CABLES2                          ESR1       TRIM23       HIP1         TRIM23       HIP1       RPS12        HIP1         CABLES2
                                                                                                                          
  PCK1                             ARRB1      ESR1         ITSN1        INTS9        ITSN1      AKT2         ITSN1        PCK1
                                                                                                                          
  MGA                              RYBP       ARRB1        YY1          TGFB1        EPN1       PAK1         MED23        MGA
                                                                                                                          
  CDK3                             YY1        YY1          E2F2         INTS10       PCK1       IRS1         FASN         CDK3
                                                                                                                          
  EPN1                             CDK3       AP2B1        RYBP         ITGB8        CABLES2    EPN1         RYBP         EPN1
                                                                                                                          
  HIP1                             HIP1       MED23        AP2B1        ESR1         AP2B1      PTAFR        CDK3         HIP1
                                                                                                                          
  ITSN1                            ITSN1      E2F2         TRIM23       DMRT3        FASN       YY1          E2F2         ITSN1
                                                                                                                          
  PTAFR                            FASN       CDK3         ESR1         CCDC25       PTAFR      HIP1         YY1          PTAFR
                                                                                                                          
  FASN                             AP2B1      FASN         ARRB1        MED23        CDK3       ITSN1        AP2B1        FASN
                                                                                                                          
  AP2B1                            E2F2       HIP1         EPN1         HIP1         ESR1       AP2B1        ESR1         TRIM23
                                                                                                                          
  **Hub genes of S~IV~ of CRC**                                                                                           
                                                                                                                          
  ATXN1                            ATXN1      MAP4         ATXN1        UBXN1        SNX2       LDB1         HIVEP1       SCAMP1
                                                                                                                          
  SMAD2                            SMAD2      ATXN1        SMAD2        ARHGEF12     PTPRK      WBSCR16      FAM193B      SMG9
                                                                                                                          
  TRIM23                           TRIM23     SMAD2        TRIM23       SF3B6        CREB1      PUM1         TRIP6        FAM208B
                                                                                                                          
  INSR                             INSR       FAM193B      INSR         AKT2         SCAMP1     LRSAM1       FAM208B      SNX2
                                                                                                                          
  YY1                              YY1        TRIM23       YY1          ANKRD28      INSR       HIVEP1       YY1          PTPRK
                                                                                                                          
  TRIP6                            TRIP6      INSR         FAM208B      PHLDA3       YY1        FAM193B      INSR         CREB1
                                                                                                                          
  FAM208B                          FAM208B    YY1          TRIP6        MAP4         RUNX1      RUNX1        TRIM23       AFAP1L1
                                                                                                                          
  SCAMP1                           SCAMP1     TRIP6        SCAMP1       TAF9         TNRC6B     TNRC6B       SMAD2        TRIM23
                                                                                                                          
  UBXN1                            UBXN1      FAM208B      SMG9         ARHGEF2      AFAP1L1    TRIP6        ATXN1        RUNX1
                                                                                                                          
  SMG9                             SMG9       UBXN1        UBXN1        YY1          ATXN1      SCAMP1       MAP4         PTPRK

Avg.ShoPat: Average shortest path length; BetCen: Betweenness centrality; CloCen: Closeness centrality; CluCoe: Clustering coefficient;  D: Degree; E: Eccentricity, NeiCon: Neighborhood connectivity; NumUndE: Number of undirected edge; TopCoe: Topological coefficient.

Cell cycle genes are remarkably involved in CRC initiation & progression {#S0013}
------------------------------------------------------------------------

The results of GO demonstrated that, except for S~II~, the cell cycle pathway is remarkably involved in CRC initiation as well as its progression. The UBI--proteasome pathway, an intracellular process involved in protein degradation, was identified as the most significant enriched term for the PPI network which made from the DEGs of S~II~. Moreover, signal transduction seems to be critical in the regulation of gene expression in S~II~ and S~III~ of CRC ([Figure 1](#F0001){ref-type="fig"}).

![**Top five functional categories (categories with p-value \< 0.05 containing at least 10 genes) that significantly enriched for each DEG list.**\
The right schematic representation of colon cancer progression is based on a model from Fearon and Vogelstein \[[@B26]\].\
DEG: Differentially expressed gene; N: Normal stage; S~I~: Stage 1; S~II: Stage\ 2;~ S~III: Stage\ 3;~ S~IV: Stage\ 4~.](fsoa-04-278-g1){#F0001}

Signaling pathway enrichment was carried out utilizing SPEED and Kyoto Encyclopedia of Genes and Genomes tools. In this step, only up-regulated DEGs were considered for pathway enrichment analyses to decipher activated signaling pathways during CRC progression. The results showed that the Wnt signaling pathway was the most significant signaling pathway in S~I~-S~III~ implying the indispensable role in initiation and progression of CRC from S~I~ to S~III~. However, this signaling pathway was not significantly enriched in S~IV~ suggesting that the metastasis of CRC is not considerably dependent on Wnt signaling pathway activity. The MAPK signaling pathway was shown to be especially active in S~I~ and S~III~. In contrast, the JAK-STAT signaling pathway was substantially enriched in the DEGs of S~II~ and S~IV~ ([Figure 2](#F0002){ref-type="fig"}).

![**Signaling pathway enrichment of the DEGs of four CRC stages.**\
MAPK signaling pathway (green line) and JAK-STAT signaling pathway (red line) had a negative correlation during colorectal cancer progression. Every significant hit in SPEED had an FDR \<0.05.\
DEG: Differentially expressed gene; CRC: Colorectal cancer; FDR: False discovery rate.](fsoa-04-278-g2){#F0002}

DEG-GO network construction for distant metastasis stage of CRC {#S0014}
---------------------------------------------------------------

The DEGs of S~IV~ were obtained from analysis of gene expression profile of this stage compared with the adjacent normal cells. The up-regulated DEGs with fold change larger than 1 and p-value smaller than 0.05 were selected for GO studies. The results of GO revealed that the cell cycle related pathways are actively involved in CRC invasion. Furthermore, gene regulatory of these DEGs with their neighbors remarkably contributed to cell proliferation events. ([Figure 3](#F0003){ref-type="fig"}).

![**Gene enrichment and network analysis of CRC\'s S~IV~ gene signature.**\
**(Left)** GO of the DEGs obtained from gene expression analysis of CRC\'s S~IV~ compared to adjacent normal tissue. **(Right)** Biological networks of these genes (green nodes) and their neighbors (gray nodes).\
GO: Gene ontology; DEG: Differentially expressed gene; CRC: Colorectal cancer; S~IV~: Stage 4](fsoa-04-278-g3){#F0003}

In order to identify the most important up-regulated DEGs involved in the aforementioned functional categories of CRC\'s S~IV~, a DEG-GO network was also reconstructed. Detailed interpretation of this network based on out-degree measure resulted in the identification of several hub genes such as *BUB1B*, *CENPE*, *CCNB1*, *FBXO5*, *MAD2L1*, *DLGP5*, *ANAPC10*, *CDK1*, *BRCA2*, *NUSAP1*, *CENPF*, *ANLN*, *NDC80* and *KIF18A* belong to the most significant enriched GO terms. The in-degree analysis of resultant DEG-GO network revealed several important intracellular molecular functions, particularly cell cycle associated pathways, as the most highly regulated pathways by the up-regulated DEGs of CRC\'s S~IV~ ([Figure 4](#F0004){ref-type="fig"}).

![**DEG-GO network constructed for up-regulated genes of CRC\'s S~IV~ when compared to its adjacent normal tissue.**\
Nodes (DEGs) with higher and lower out-degree measures are shown in bigger and smaller circles, respectively. Nodes (GO terms) with higher in-degree measures are indicated in dark colors, while nodes with lower in-degree measures are shown in bright colors.\
DEG: Differentially expressed gene; GO: Gene ontology; CRC: Colorectal cancer; SIV: Stage 4.](fsoa-04-278-g4){#F0004}

The S~I~-S~IV~ of CRC share a high number of common genes {#S0015}
---------------------------------------------------------

Clustering analysis of the DEGs obtained from each CRC stage compared to the respective normal tissues revealed that the four studied CRC stages (S~I~-S~IV~) share a notable number of overlapped genes involved in multiple cellular processes. Prior to clustering, up-regulated and down-regulated DEGs were determined and separated. The results of clustering identified 817 (24.2%) common up-regulated DEGs and 490 (19%) common down-regulated DEGs in all studied CRC stages. Nevertheless, the highest proportion of common genes was observed between S~I~, S~II~ and S~III~ (1274 genes among up-regulated DEGs and 774 genes among down-regulated DEGs) ([Figure 5](#F0005){ref-type="fig"}).

![**Clustering of CRC stages according to their gene signatures.**\
Clustering of **(A)** up-regulated and **(B)** down-regulated DEGs resulted from preprocessing of CRC\'s S~I~-S~IV~ compared to their adjacent normal tissues.\
CRC: Colorectal cancer; DEG: Differentially expressed gene.](fsoa-04-278-g5){#F0005}

Functional annotation of these common genes indicated that the majority of common up-regulated genes were actively involved in regulation of cell cycle (94 genes) and mitosis (57 genes). However, several other pathways such as regulation of RNA processing, DNA repair and protein metabolism were also significantly enriched. In contrast, the common down-regulated DEGs obviously participated in the regulation of apoptosis and intracellular signaling cascade (results not shown). Detailed analysis of these genes indicated that 21 genes (out of 94 genes) have a direct role in cell cycle pathway ([Figure 6](#F0006){ref-type="fig"}).

![**Relationship between cell cycle and common up-regulated DEGs identified between S~I~-S~IV~ of CRC (red color).**\
Activation, inhibition and undirected interactions are shown with solid green lines, solid red lines and dotted black lines, respectively. The cell cycle pathway was extracted from KEGG database.\
DEG: Differentially expressed gene; S~I~-S~IV~: Stage 1 to Stage 4; CRC: Colorectal cancer; KEGG: Kyoto Encyclopedia of gene and genome.](fsoa-04-278-g6){#F0006}

The main subnetwork was extracted from the PPI network constructed for common up-regulated DEGs and is depicted in [Supplementary Figure 2](http://www.future-science.com/doi/suppl/10.4155/fsoa-04-278-s1.docx). Calculation of several centrality measures such as Betweenness centrality and degree showed that *CAND1* gene is the most significant hub gene in the subnetwork. However, some other genes including *CDK2*, *EED*, *BRCA1*, *CDK1*, *BARD1*, *SRPK1*, *NPM1*, *PCNA*, *SRSF2*, *EZH2*, *HNRNPA1*, *HIST1H4C* and *HNRNPU* were also distinguished as important hub genes.

The enriched cellular functions for the SI-SIV common genes were examined. Our observations revealed that cell proliferation and apoptosis are the most significant functional categories enriched in common up-regulated and down-regulated genes, respectively. We further compared the expression levels of these genes during S~I~--S~IV~ of CRC. The results indicated that cell proliferation genes had the highest expression levels in S~I~ and S~IV~. However, apoptosis-related genes are down-regulated in S~III~ of CRC. *ANLN* and *CDK1* genes had the highest overexpression level in all CRC stages compared with adjacent normal cells, whereas *STAT1* was the most down-regulated gene in all CRC stages ([Supplementary Figure 3](http://www.future-science.com/doi/suppl/10.4155/fsoa-04-278-s1.docx)).

*ATXN1* &*CDK1* have significantly deregulated in metastatic SW620 cells {#S0016}
------------------------------------------------------------------------

The expression levels of *ATXN1* and *CDK1* were normalized to the level of the *GAPDH* housekeeping gene which showed the most homogenous expression in both SW620 and NCM460 cell lines. Consistent with our bioinformatics analyses, the results of real-time PCR indicated that the expression of *ATXN1* (down-regulated, p-value \< 0.001) and *CDK1* (up-regulated, p-value \< 0.05) have significantly altered in metastatic SW620 cells compared with the normal colon NCM460 cells ([Figure 7](#F0007){ref-type="fig"}). This *in vitro* validation suggests that the introduced novel biomarkers of CRC can be reliably considered to be promising candidates for therapeutic applications.

![**Gene expression analysis using qRT-PCR.**\
Expression level of **(A)** *ATXN1* and **(B)** *CDK1* in SW620 and NCM460 cell lines. Changes in expression level were found to be significant (p \< 0.05).\
qRT-PCR: Quantitative real-time PCR.](fsoa-04-278-g7){#F0007}

Discussion {#S0017}
==========

Our study was aimed at modeling CRC initiation and invasion using deep analyses of microarray data. The results of this *in silico* study propose several potential candidates for the treatment of CRC as well as early diagnosis of this cancer. Consistent with previous studies, we found numerous important regulatory genes and transcription factors associated with CRC progression. These findings provide support for the efficiency of systems biology approaches in the identification of novel CRC biomarkers.

We found out that *CDK1*, *UBC*, *ESR1* and *ATXN1* are the most important hub genes of S~I~, S~II~, S~III~ and S~IV~ of CRC, respectively. Among these hub genes, *CDK1* and *UBC* were up-regulated in CRC samples compared with adjacent normal cells, while *ESR1* and *ATXN1* were down-regulated. *CDK1* is a member of Cyclin-dependent kinases (CDKs) family, which are serine/threonine kinases whose deregulation is associated with cancer progression. Hence, these cell cycle regulators have been targeted in a variety of human cancers \[[@B27]\]. Studies have shown that inhibition of *CDK1* enhances the sensitivity of CRC cells to anticancer compounds through caspase-dependent signaling pathways \[[@B28],[@B29]\]. The *UBC*, also called second ubiquitin-conjugating enzyme or E2, is a member of ubiquitin-proteasome degradation system which contributes to the regulation of cell proliferation by mediating the selective degradation of target proteins. This enzyme also catalyzes a particular type of polyubiquitination, 'Lys-63'-linked polyubiquitination, which does not result in protein degradation and leads to an enhanced cell survival through regulating cell cycle and DNA repair pathways \[[@B30],[@B31]\]. Therefore, up-regulation of *UBC* may enhance the survival of CRC cell through maintaining the cell cycle and DNA repair abilities of the cell. *ESR1* is a nuclear hormone receptor that encodes estrogen receptor α involved in the regulation eukaryotic cell proliferation and differentiation. Although, *ESR1* is frequently amplified in breast cancer cells \[[@B32]\], methylation-dependent silencing of this gene by CGI (CpG island) has been previously reported \[[@B33]\]. CGI regions are unmethylated short and dispersed sequences of DNA with a high frequency of CpG dinucleotides which are highly associated with the bulk genome. Furthermore, evaluation of the *ESR1* methylation status uncovered that significant methylation of this gene occurred in patients with CRC and is associated with markedly diminished *ESR1* expression in colorectal tumors examined \[[@B34]\]. This suggests the possibility of tumor suppressor activity for *ESR1* in CRC. Accordingly, estrogens might reduce CRC development via preventing the DNA methylation of *ESR1* \[[@B35]\]. *ATXN1* is a chromatin-binding factor that functions as a corepressor involved in transcriptional repression by directly repressing *CBF1*, a transcription factor that is crucial for the Notch signaling pathway \[[@B36]\]. It is now widely accepted that Notch pathway is substantially required for initiation of CRC as well as maintenance and self-renewal of CRC initiating cells \[[@B37]\]. Furthermore, Sonoshita *et al*. found that activation of *DAB1/Dab1*, a Notch signaling target gene, can promote CRC invasion and metastasis \[[@B38]\]. Kim and colleagues have found a negative crosstalk between Notch and Wnt/β-catenin signaling pathways \[[@B39]\]. Interestingly, the signaling pathway enrichment revealed that Wnt signaling is actively involved in regulation of S~I~, S~II~ and S~III~ of CRC, but the activity of this signaling pathway has significantly diminished during S~IV~.

Wnt signaling pathway was found to be a key player in the initiation and progression on CRC, but not in metastasis stage. It is now well understood that Wnt signaling is a critical event for initiating the genesis of most CRCs, especially through loss of its negative regulator, Adenomatous Polyposis Coli \[[@B40]\]. Moreover, both β-catenin-dependent and β-catenin-independent Wnt signaling enhance CRC progression via regulating epithelial--mesenchymal transition \[[@B41]\]. For decades, components of this signaling pathway served as interesting targets in human CRC. In addition to the importance of Wnt signaling pathway, we found a negative correlation between JAK-STAT and MAPK signaling pathways during CRC progression suggesting a dual regulatory role of JAK-STAT/MAPK cascades in CRC progression and invasion. Wu and colleagues reported that cooperation of PAR2/MAPKs/NF-κB signal transduction pathways promotes proliferation and migration of colon cancer cell line SW620 \[[@B42]\]. The crosstalk between these signaling pathways is complex and each pathway can regulate the activation of the other at multiple levels. Consistent with this, Krasilnikov and colleagues have found that PI3K and MAPK signaling down-regulate JAK-STAT signaling in human melanoma cells via inhibiting tyrosine phosphorylation of JAK/STATs \[[@B43]\]. However, *STAT1* was identified as the most down-regulated gene in all CRC stages. In our previous study, this gene was also found to be down-regulated in metastatic CRC samples compared with the nonmetastatic samples. Modular analyses of CRC metastasis-derived PPI network corroborated that *STAT1* functions in one of the most important protein complexes correlated with CRC metastasis \[[@B7]\]. Considering the role of MAPK and JAK-STAT signaling pathways in the regulation of cell proliferation, we suggest that down-regulation of each pathway is recouped by activation of the other pathway. This mechanism of regulation may be indispensable for providing the favorable microenvironment for CRC development \[[@B44],[@B45]\].

Interestingly, the clustering analyses demonstrated a remarkable overlap between all studied CRC stages. Functional annotation of common DEGs revealed that majority of common up- and down-regulated genes are obviously contributed to the regulation of cell proliferation and apoptosis, respectively. *CAND1*, *CDK2*, *EED*, *BRCA1* and *BARD1* were identified as the most important hub genes up-regulated in all CRC stages. Several evidence have indicated the disruption of *CAND1* in prostate cancer \[[@B46]\]. Nevertheless, the function of this gene in CRC has poorly been investigated. *CDK2* is a serine/threonine kinase which its activity is dispensable for controlling cell cycle and mitosis \[[@B47]\]. Inhibition of *CDK2* in CRC is substantially associated with enhanced cell death and suppressed cell proliferation implying its crucial function in CRC development \[[@B48],[@B49]\]. Consistent with our results, *EED* and *BARD1* have been proposed as promising prognostic markers in CRC and their expression correlate with CRC progression and aggressive clinical behavior \[[@B50],[@B51]\]. *BARD1* is an E3 ubiquitin-protein ligase which acts as a heterodimer with *BRCA1* (*BRCA1*-*BARD1*). This protein heterodimer mediates the formation of 'Lys-6'-linked polyubiquitin chains, and subsequently regulates a wide range of intracellular pathways such as DNA repair, regulation of protein degradation, transcription and genomic stability \[[@B52],[@B53]\].

Conclusion {#S0018}
==========

Our findings suggest a dynamic model of CRC initiation, progression and invasion. The results were highly compatible with previous studies. Moreover, several novel biomarkers were also proposed for each stage of CRC. The cell cycle and signal transduction genes were apparently involved in regulation of CRC stages. Moreover, Wnt, MAPK and JAK-STAT signaling pathways seemed to be crucial in the regulation of CRC stages. However, the results of this study need to be investigated in greater details by further experimental methods.

Future perspective {#S0019}
==================

Despite decades of investigations, clinicians are still faced with numerous challenges in the diagnosis and treatment of patients with a specific stage of CRC. This might be due to deregulation of particular gene signatures in each CRC stage. Thus, identification of drug targets based on molecular mechanisms of each CRC stage can be very helpful in targeted therapy of CRC. In this study, we separately analyzed gene expression profiles of each CRC stage (i.e., S~I~-S~IV~) and integrated the results of gene expression analysis with PPI networks. Several genes and regulatory networks were found in each CRC stage. Cell cycle and signal transduction genes showed critical roles in early stages of CRC. Intriguingly, a crosstalk between MAPK and JAK-STAT signaling pathways during CRC progression was also predicted *in silico*. Although, a part of *in silico* findings was validated *in vitro*, there is a need to further validate this study\'s results. Moreover, parallel analysis of other datasets (e.g., microarray or next generation sequencing data) would increase the reliability of these predictions.

###### Summary points

**Background** {#S0020}
--------------

-   Rapid and robust screening for biomarkers in each stage of colorectal cancer (CRC) may result in early diagnosis and reliable treatment programs.

-   Computational integration of gene expression profiles with protein--protein interaction networks have shown robustness in identifying key target genes and regulatory networks in human cancers.

**Experiment** {#S0021}
--------------

-   Microarray dataset GSE21510 was obtained from gene expression omnibus database and analyzed with GEO2R.

-   Cytoscape and FunRich packages were used for construction and analyses of protein--protein interaction networks.

-   BiNGO, SPEED and DAVID tools were used for functional enrichment of differentially expressed genes.

**Results & discussion** {#S0022}
------------------------

-   *CDK1*, *UBC*, *ESR1* and *ATXN1* genes were detected as the most significant hub genes of S~I~, S~II~, S~III~ and S~IV~ of CRC, respectively.

-   Cell cycle genes were highly involved in S~I~-S~III~ of CRC suggesting their crucial role in CRC initiation and progression.

-   Wnt signaling pathway was particularly enriched in S~I~-S~III~, but not in S~IV~. Whereas, MAPK and JAK-STAT signaling pathways had a negative correlation during CRC stages.

-   A high number of common genes were identified between S~I~, S~II~ and S~III~ implying their close biological properties.

-   Some *in silico* findings were validated *in vitro* implicating that the results of this study can be used in CRC diagnosis and prevention programs.

Supplementary Material
======================

###### 

Click here for additional data file.
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